These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 8996340

  • 1. A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer.
    Gruenwald IE, Stein A, Rashcovitsky R, Shifroni G, Lurie A.
    J Urol; 1997 Feb; 157(2):487-91. PubMed ID: 8996340
    [Abstract] [Full Text] [Related]

  • 2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 3. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 6. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 7. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
    Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K, Kohri K.
    J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K.
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [Abstract] [Full Text] [Related]

  • 12. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A, Bock PR.
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.